10th RSA drug, Stivarga’ applied for health insurance on GIST patients

Stivarga Tab 40mg(regorafenib), a Bayer’s gastrointestinal stromal tumor(GIST) therapy, is going to be registered for the health insurance benefit from the 1^st next month.

It will become the 10^th drug with the risk-sharing agreement established.

The Ministry of Health and Welfare(MOHW) held the National Health Insurance Policy Deliberation Committee on the 10^th, and decided the amendment as t...